Dermata Therapeutics (DRMA) Assets Average (2021 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Assets Average of $7.7 million for Q1 2026, up 13.23% year-over-year from $6.8 million in Q1 2025, and up 18.51% quarter-over-quarter from $6.5 million in Q4 2025.
Dermata Therapeutics (DRMA) Assets Average (2021 - 2026) Analysis & Trends
Dermata Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $7.7 million for Q1 2026.
- In Q1 2026, Assets Average rose 13.23% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 13.23% YoY), while the FY2025 annual figure was $5.7 million, down 1.0% from the prior year.
- Assets Average for Q1 2026 stood at $7.7 million, up from $6.5 million in the prior quarter.
- The five-year high for Assets Average was $10.3 million in Q1 2022, with the low at $5.1 million in Q4 2024.
- The 5-year median for Assets Average is $7.7 million (2026), against an average of $7.6 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average sank 42.16% in 2024, then jumped 59.8% in 2025.
- Dermata Therapeutics' Assets Average stood at $8.0 million in 2022, then dropped by 3.88% to $7.7 million in 2023, then plunged by 33.2% to $5.1 million in 2024, then climbed by 26.55% to $6.5 million in 2025, then gained by 18.51% to $7.7 million in 2026.
- Business Quant data shows DRMA's Assets Average at $7.7 million in Q1 2026, $6.5 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 6.47 Mn |
| Sep 30, 2025 | 5.86 Mn |
| Jun 30, 2025 | 8.32 Mn |
| Mar 31, 2025 | 6.77 Mn |
| Dec 31, 2024 | 5.11 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 5.21 Mn |
| Mar 31, 2024 | 6.58 Mn |
| Dec 31, 2023 | 7.65 Mn |
| Sep 30, 2023 | 8.02 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Mar 31, 2023 | 8.12 Mn |
| Dec 31, 2022 | 7.96 Mn |
| Sep 30, 2022 | 10.00 Mn |
| Jun 30, 2022 | 10.04 Mn |
| Mar 31, 2022 | 10.33 Mn |
| Dec 31, 2021 | 12.65 Mn |
| Sep 30, 2021 | 7.41 Mn |